Fenofibrate anti-RARα/RXRα dimerization to attenuate all-trans retinoic acid-induced hyperlipidemia and hepatic steatosis in mice
Cellular Signalling · 2026
DOI: 10.1016/j.cellsig.2026.112357 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2026. Verfasst von Qian Lu und 11 weiteren Autor:innen. Beteiligte Einrichtung: New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009…. Hauptthemen laut MEDLINE: Fenofibrate, Tretinoin, Retinoic Acid Receptor alpha, Hyperlipidemias. Die Arbeit nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangsu Province Natural Science Foundation, Graduate Research and Innovation Projects of Jiangsu Province.
Abstract (Originalsprache)
All-trans retinoic acid (ATRA), the active metabolite of vitamin A, serves as the first-line therapy for acute promyelocytic leukemia (APL) in clinical. However, increasing clinical evidence indicates that ATRA treatment is frequently associated with dyslipidemia, the underlying molecular mechanisms of which remain unclear. Fenofibrate, a specific agonist of peroxisome proliferator-activated receptor alpha (PPARα), is widely used in the management of metabolic disorders, yet its potential to alleviate ATRA-induced lipid abnormalities has not been fully elucidated. In this study, we established a mouse model of ATRA-induced hyperlipidemia and hepatic steatosis to investigate the underlying mechanisms and assess the therapeutic effects of fenofibrate as a combinatorial agent. Our findings revealed that ATRA promoted the formation of RARα/RXRα heterodimers, which activated the hepatic FOXO1-APOCIII pathway, leading to hyperlipidemia and hepatic lipid accumulation in mice. Fenofibrate effectively counteracted these effects by activating PPARα, thereby competitively inhibiting RARα binding to RXRα and restoring lipid homeostasis. This study reveals a novel mechanism underlying ATRA-induced hyperlipidemia and hepatic lipid accumulation, which offers a theoretical foundation for the clinical use of fenofibrate in managing ATRA-induced hyperlipidemia and hepatic steatosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
- New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China; Key Laboratory of Drug Quality Control and Pharmacovigilance,…
- New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China. Electronic address: yuqinwei7213@cpu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Jiangsu Province Natural Science Foundation
- Graduate Research and Innovation Projects of Jiangsu Province
- China Postdoctoral Science Foundation
- Double First Class University Plan
Zitieren
APA
Lu, Q., Xia, N., Wang, J., Yi, Y., Fan, X., Jin, M., Huang, X., Xin, W., Sun, L., Hu, J., Jiang, Z., & Yu, Q. (2026). Fenofibrate anti-RARα/RXRα dimerization to attenuate all-trans retinoic acid-induced hyperlipidemia and hepatic steatosis in mice. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2026.112357
Vancouver
Lu Q, Xia N, Wang J, Yi Y, Fan X, Jin M, et al. Fenofibrate anti-RARα/RXRα dimerization to attenuate all-trans retinoic acid-induced hyperlipidemia and hepatic steatosis in mice. Cellular Signalling. 2026. doi:10.1016/j.cellsig.2026.112357
BibTeX
@article{Lu2026,
author = {Lu, Qian and Xia, Ninglin and Wang, Jicheng and Yi, Yulin and Fan, Xue and Jin, Ming and Huang, Xiaofei and Xin, Wenwen and Sun, Li and Hu, Jinyu and Jiang, Zhenzhou and Yu, Qinwei},
title = {Fenofibrate anti-RARα/RXRα dimerization to attenuate all-trans retinoic acid-induced hyperlipidemia and hepatic steatosis in mice},
journal = {Cellular Signalling},
year = {2026},
doi = {10.1016/j.cellsig.2026.112357}
}
EUVIMED